Early, disease-modifying treatment and detection for amyloid diseases.
We’re targeting early molecular triggers of Alzheimer’s, Parkinson’s, and many other amyloid diseases…aiming to change their course, even before symptoms.
Alpha (α)-sheet. The missing link.
We have a different approach. We’re recasting the amyloid hypotheses.

Our work, decades in the making, is based on the discovery of α-sheet, a defining feature of toxic oligomers – an early molecular trigger of amyloid diseases.
Targeting a needle in the haystack.
We’re developing a highly-selective, α-sheet targeting platform utilizing custom-designed peptides for therapeutics and diagnostics.
Amazing Minds. Big Impact.
We’re working together to make breakthroughs that will change the course of amyloid diseases affecting over a billion people around the globe.

What's AltPep?

Go to About AltPep

We are a group of innovators working to transform the diagnosis and treatment of amyloid diseases, enabling action earlier than ever thought possible. Our lead programs focus on Alzheimer’s and Parkinson’s diseases, with other amyloid diseases on the horizon.

We are a group of innovators working to transform the diagnosis and treatment of amyloid diseases, enabling action earlier than ever thought possible.

Our lead programs focus on Alzheimer’s and Parkinson’s diseases, with other amyloid diseases on the horizon.

Our Approach

Go to Approach

Tackling early detection and treatment for amyloid diseases.

The AltPep platform, the foundation of our diagnostic and therapeutic programs, is based on a growing library of custom designed synthetic peptides. 

Our customized, synthetic peptides are designed to bind selectively to α-sheet toxic soluble oligomers to both detect and neutralize them early, and throughout disease progression.

Pipeline

Go to Pipeline

Therapeutics + Diagnostics Platform

SOBIN Therapeutics

In development for use in concert with early detection to target and neutralize the toxic soluble oligomers associated with amyloid diseases.

SOBA Diagnostics

Highly sensitive, simple blood tests in development to aid in the detection of amyloid diseases.

Our pipeline of therapeutics and diagnostics for amyloid disease starts with Alzheimer’s and Parkinson’s.

Recent News

All News

AltPep Corporation Presents New Preclinical Data at CTAD 2025 Demonstrating SOBIN-AD, its Custom-Designed Peptide for Alzheimer’s Disease, Improves Behavior in Both Symptomatic and Asymptomatic Disease

December 1, 2025

AltPep Corporation, a privately held biotechnology company developing early disease-modifying treatments and detection tools for amyloid diseases, will present preclinical data at the Clinical Trials on Alzheimer’s Disease Conference (CTAD), taking place December 1-4 in San Diego, CA, further reinforcing the promising potential of its lead compound, SOBIN-AD (Soluble Oligomer Binding INhibitor), as a treatment for early Alzheimer’s disease (AD).

Read More
All News
  • Follow Us
Linkedin

General Inquiries

Career Inquiries

Partnering/BD Inquiries

Clinical Test Inquiries

  • Follow Us
Linkedin
©2026 AltPep Corporation. All rights reserved.

ALTPEP, SOBIN, and SOBA are trademarks of AltPep Corporation. 

Biotech Website Design

The Risk of AIRA

Amyloid plaque are targeted and mobilized by anti-amyloid antibodies (such as lecanamab and donanamab). The antibody-bound plaque clear through the brain’s immune cells, called microglia, by binding Fc-gamma Receptors (FCgRs). (Alzheimers Dis Rep. 2023) This binding alters the microglia resulting in inflammation and cytokine storm and thereby creating a high risk of ARIA (https://ajronline.org/doi/epdf/10.2214/AJR.22.28461).

Linkedin-in

Valerie Daggett, PhD

Chief Executive Officer

Valerie, the CEO/Founder of AltPep and an Endowed Professor of Bioengineering at the University of Washington, has been a champion of groundbreaking research for over 30 years. Her inherent curiosity pushes her to uncover new ways of tackling problems in the field of amyloid diseases, where successes are few.  Her tenacity led to a revolutionary discovery of a protein structure that could dramatically change the diagnosis and treatment of Alzheimer’s disease and over 50 other amyloid diseases. At AltPep, Valerie leads a team of innovators who are developing this platform to make the early, pre-symptomatic diagnosis and treatment of amyloid diseases a reality. Valerie holds a BA from Reed College, PhD from the University of California, San Francisco, and was a Postdoctoral Fellow at Stanford University.